Trials / Unknown
UnknownNCT04871828
The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19)
The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19): (Randomized Clinical Trial)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- King Abdullah International Medical Research Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
There is an urgent need to explore therapeutic options for SARS-CoV-2 in order to face the pandemic. The selected intervention was based on that zafirlukast will have dual effect; first it will block the virus replication through inhibiting the COVID19 helicase that is involved in virus replication and secondly by reducing the inflammation through antagonizing the leukotriene receptor. The purpose of this study is to evaluate the clinical efficacy and safety of Leukotriene receptor antagonist in the treatment of moderate cases of COVID-19 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Leukotriene Receptor Antagonist | Zafirlukast |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2021-02-28
- Primary completion
- 2021-09-01
- Completion
- 2021-12-01
- First posted
- 2021-05-04
- Last updated
- 2021-05-10
Locations
1 site across 1 country: Saudi Arabia
Source: ClinicalTrials.gov record NCT04871828. Inclusion in this directory is not an endorsement.